{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:16:03Z","timestamp":1793643363088,"version":"4.5.1"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Biosimilars are increasingly available for the treatment of many serious disorders, however some concerns persist about switching a patient to a biosimilar whose condition is stable while on the reference biologic. Randomized controlled studies and extension studies with a switch treatment period (STP) to or from a biosimilar and its reference biologic were identified from publicly available information maintained by the U.S. Food and Drug Administration (FDA). These findings were augmented with data from peer reviewed publications containing information not captured in FDA reviews. Forty-four STPs were identified from 31 unique studies for 21 different biosimilars. Data were extracted and synthesized following PRISMA guidelines. Meta-analysis was conducted to estimate the overall risk difference across studies. A total of 5,252 patients who were switched to or from a biosimilar and its reference biologic were identified. Safety data including deaths, serious adverse events, and treatment discontinuation showed an overall risk difference (95% CI) of -0.00 (-0.00, 0.00), 0.00 (-0.01, 0.01), -0.00 (-0.01, 0.00) across STPs, respectively. Immunogenicity data showed similar incidence of anti-drug antibodies and neutralizing antibodies in patients within a STP who were switched to or from a biosimilar to its reference biologic and patients who were not switched. Immune related adverse events such as anaphylaxis, hypersensitivity reactions, and injections site reactions were similar in switched and non-switched patients. This first systematic review using statistical methods to address the risk of switching patients between reference biologics and biosimilars finds no difference in the safety profiles or immunogenicity rates in patients who were switched and those who remained on a reference biologic or a biosimilar.<\/jats:p>","DOI":"10.1371\/journal.pone.0292231","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:29:38Z","timestamp":1696339778000},"page":"e0292231","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":70,"title":["Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2677-9255","authenticated-orcid":true,"given":"Thomas M.","family":"Herndon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ausin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina N.","family":"Brahme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Schrieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances C.","family":"Andrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Grosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Stacey","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,10,3]]},"reference":[{"key":"pone.0292231.ref001","unstructured":"U.S. Food and Drug Administration. Statement from Sarah Yim, M.D., acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA\u2019s Center for Drug Evaluation and Research, on FDA\u2019s continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product Silver Spring, MD: U.S. Food and Drug Administration; 2019 [updated November 15, 2019. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-sarah-yim-md-acting-director-office-therapeutic-biologics-and-biosimilars-fdas-center-drug."},{"key":"pone.0292231.ref002","unstructured":"U.S. Food and Drug Administration. Biosimilar and Interchangeable Products Silver Spring, MD: U.S. Food and Drug Administration; 2021 [Available from: https:\/\/www.fda.gov\/consumers\/consumer-updates\/biosimilar-and-interchangeable-biologics-more-treatment-choices."},{"issue":"4","key":"pone.0292231.ref003","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.37765\/ajmc.2022.88869","article-title":"Patients\u2019 Access to 2018 FDA-Approved Drugs 1 Year Post Approval","volume":"28","author":"AD Panzer","year":"2022","journal-title":"American Journal of Managed Care"},{"key":"pone.0292231.ref004","unstructured":"U.S. Food and Drug Administration. Biosimilar Product Information Silver Spring, MD: U.S. Food and Drug Administration; 2022 [Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information."},{"issue":"7","key":"pone.0292231.ref005","doi-asserted-by":"crossref","first-page":"329","DOI":"10.37765\/ajmc.2022.88809","article-title":"Projected US Savings from Biosimilars, 2021\u20132025","volume":"28","author":"A Mulcahy","year":"2022","journal-title":"American Journal of Managed Care"},{"issue":"2","key":"pone.0292231.ref006","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/rheumatology\/keaa502","article-title":"US rheumatologists\u2019 beliefs and knowledge about biosimilars: A survey","volume":"60","author":"A Gibofsky","year":"2021","journal-title":"Rheumatology (United Kingdom)"},{"key":"pone.0292231.ref007","article-title":"The efficacy, safety and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review","author":"L Barbier","year":"2020","journal-title":"Clinical pharmacology and therapeutics"},{"issue":"4","key":"pone.0292231.ref008","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40265-018-0881-y","article-title":"Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes","volume":"78","author":"HP Cohen","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"pone.0292231.ref009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apt.14997","article-title":"Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab","volume":"49","author":"BG Feagan","year":"2019","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"16","key":"pone.0292231.ref010","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s40265-021-01601-2","article-title":"Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective","volume":"81","author":"P Kurki","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"pone.0292231.ref011","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40744-019-00190-7","article-title":"Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?","volume":"7","author":"R Fleischmann","year":"2020","journal-title":"Rheumatology and Therapy"},{"key":"pone.0292231.ref012","article-title":"Revisiting Interchangeability to Realize the Benefit of Biosimilars","author":"B Canter","year":"2021","journal-title":"Duke Margolis Center for Health Policy"},{"key":"pone.0292231.ref013","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Considerations in demonstrating interchangeability with a reference product Silver Spring, MD. 2019."},{"key":"pone.0292231.ref014","unstructured":"Agency MaHpR. Guidance on the licensing of biosimilar products. London, United Kingdom; 2022."},{"key":"pone.0292231.ref015","unstructured":"Food and Drug Administration. Reviewer Guidance on Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review; Availability. Rockville, MD. 2005."},{"issue":"1","key":"pone.0292231.ref016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"MJ Page","year":"2021","journal-title":"Systematic Reviews"},{"key":"pone.0292231.ref017","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"GA Wells","year":"2000","journal-title":"Oxford"},{"issue":"7796","key":"pone.0292231.ref018","first-page":"535","article-title":"Risk of recurrence after venous thromboembolism in men and women: Patient level meta-analysis","volume":"342","author":"J Douketis","year":"2011","journal-title":"BMJ"},{"key":"pone.0292231.ref019","doi-asserted-by":"crossref","unstructured":"Whitehead A. Dealing with heterogeneity. In: Whitehead A, editor. Meta-Analysis Of Controlled Clinical Trials. 1st ed. New York, New York: John Wiley & Sons, Ltd; 2002. p. 151\u201374.","DOI":"10.1002\/0470854200.ch6"},{"issue":"11","key":"pone.0292231.ref020","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/sim.4780101105","article-title":"A general parametric approach to the meta-analysis of randomized clinical trials","volume":"10","author":"A Whitehead","year":"1991","journal-title":"Statistics in Medicine"},{"issue":"3","key":"pone.0292231.ref021","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"CONTROL CLIN"},{"issue":"1","key":"pone.0292231.ref022","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/annonc\/mdx638","article-title":"Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: A phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy","volume":"29","author":"K Blackwell","year":"2018","journal-title":"Annals of Oncology"},{"issue":"1","key":"pone.0292231.ref023","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1857-3","article-title":"An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis","volume":"21","author":"S Cohen","year":"2019","journal-title":"Arthritis Research and Therapy"},{"issue":"11","key":"pone.0292231.ref024","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/acr.23586","article-title":"Extension Study of PF-05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis","volume":"70","author":"SB Cohen","year":"2018","journal-title":"Arthritis Care and Research"},{"issue":"2","key":"pone.0292231.ref025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40259-019-00403-z","article-title":"Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179\/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54\u201378 Data From a Randomized, Double-Blind, Phase III Trial","volume":"34","author":"SB Cohen","year":"2020","journal-title":"BioDrugs"},{"issue":"12","key":"pone.0292231.ref026","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1136\/annrheumdis-2017-211591","article-title":"Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4","volume":"76","author":"P Emery","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"pone.0292231.ref027","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.2215\/CJN.11631017","article-title":"Intravenous epoetin alfa-epbx versus epoetin alfa for treatment of anemia in end-stage kidney disease","volume":"13","author":"S Fishbane","year":"2018","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"1","key":"pone.0292231.ref028","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02626-4","article-title":"Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira\u00ae) or continuing biosimilar therapy: week 52\u201392 data from a randomized, double-blind, phase 3 trial","volume":"23","author":"RM Fleischmann","year":"2021","journal-title":"Arthritis Research and Therapy"},{"issue":"6","key":"pone.0292231.ref029","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/joim.12880","article-title":"Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial","volume":"285","author":"GL Goll","year":"2019","journal-title":"Journal of Internal Medicine"},{"issue":"1","key":"pone.0292231.ref030","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1907-x","article-title":"Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study","volume":"21","author":"J Jaworski","year":"2019","journal-title":"Arthritis Research and Therapy"},{"issue":"10086","key":"pone.0292231.ref031","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"KK J\u00f8rgensen","year":"2017","journal-title":"The Lancet"},{"issue":"2","key":"pone.0292231.ref032","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clml.2021.08.005","article-title":"Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. Clinical Lymphoma","volume":"22","author":"LW Kwak","year":"2022","journal-title":"Myeloma and Leukemia"},{"issue":"6","key":"pone.0292231.ref033","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/bjd.15857","article-title":"Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis","volume":"177","author":"K Papp","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"pone.0292231.ref034","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","article-title":"Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study","volume":"76","author":"W Park","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"pone.0292231.ref035","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/rheumatology\/kez152","article-title":"Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial","volume":"58","author":"SC Shim","year":"2019","journal-title":"Rheumatology (United Kingdom)"},{"issue":"3","key":"pone.0292231.ref036","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000492621","article-title":"Switching from epoetin alfa (Epogen\u00ae) to epoetin alfa-epbx (RetacritTM) using a specified dosing algorithm: A randomized, non-inferiority study in adults on hemodialysis","volume":"48","author":"R Thadhani","year":"2018","journal-title":"American Journal of Nephrology"},{"issue":"7","key":"pone.0292231.ref037","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1470-2045(18)30241-9","article-title":"Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial","volume":"19","author":"G von Minckwitz","year":"2018","journal-title":"The Lancet Oncology"},{"issue":"6","key":"pone.0292231.ref038","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/art.40444","article-title":"Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two\u2013Week Phase III Randomized Study Results","volume":"70","author":"ME Weinblatt","year":"2018","journal-title":"Arthritis and Rheumatology"},{"issue":"6","key":"pone.0292231.ref039","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40259-020-00447-6","article-title":"Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study","volume":"34","author":"P Wiland","year":"2020","journal-title":"BioDrugs"},{"issue":"10182","key":"pone.0292231.ref040","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","article-title":"Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, phase 3 non-inferiority study","volume":"393","author":"BD Ye","year":"2019","journal-title":"The Lancet"},{"issue":"2","key":"pone.0292231.ref041","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","article-title":"Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study","volume":"76","author":"DH Yoo","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"pone.0292231.ref042","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Scientific considerations in demonstrating biosimilarity to a reference product. Silver Spring, MD. 2015."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0292231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:30:01Z","timestamp":1696339801000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0292231"}},"subtitle":[],"editor":[{"given":"Enrique","family":"Teran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,10,3]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0292231","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,3]]}}}